Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues
Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,
Gilead Q4 Earnings Highlights: Remdesivir Sales Fall 30%, Raises Dividend, FY22 EPS Below Estimates
Gilead Sciences Inc (NASDAQ: GILD) posted